heightened

PairedWorld Foundation Unveils Innovative Solution to Digital Addiction and Loneliness during World Economic Forum and Announces Key Additions to Its Board and Strategic Partnerships

Source Node:
Time Stamp: January 29, 2024 6:29 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

Davos, Switzerland – As the World Economic Forum Annual Meeting 2024 has come to an end, a critical theme has resonated throughout the discussions: the deep and complex relationship between technology and modern society. Key topics, such as the escalating issues of digital addiction, loneliness, and isolation, sparked intense debates. Initiatives like Human Change, along with dialogues among the world's tech leaders about technology's potential to enhance humanity, have set the stage. Leading this charge, the PairedWorld Foundation unveiled its innovative approach, marking a significant milestone in harnessing emerging technology

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

CYGNI: ALL GUNS BLAZING RELEASE CONFIRMED ON PLAYSTATION®5 and In 2023 XBOX SERIES X | S and STEAM®

Source Node:
Time Stamp: August 25, 2022 7:15 AM - Modified On: August 25, 2022 - Published By:
Source Cluster:
Republished By Plato

Konami and Keelworks have confirmed the platforms for an early 2023 release along with a new intro video and walkthrough from the developers at Gamescom. Konami Digital Entertainment B.V. And Scotland-based studio KeelWorks Ltd today released a slew of new details for "CYGNI: All Guns Blazing" as part of gamescom. Following on from the previous reveal of the game that can be played in the show at the TikTok booth. CYGNI: All Guns Blazing is a double-stick vertical shooter with next-generation graphics, Hollywood-level animation, and intense action. CYGNI, previously announced